KalVista FY2022 net loss $82.3M (-$3.36/share); cash $166.2M; sebetralstat Phase 3 on track

KalVista Pharmaceuticals, Inc.

Net loss $82.3M ($3.36 loss per share) vs $46.2M ($2.42) prior year; R&D spend $70.2M.
Cash & marketable securities $166.2M at April 30, 2022, down from $248.9M; funding into early 2024.
Sebetralstat Phase 3 KONFIDENT trial enrollment on track; data expected H2 2023. EU orphan designation received.
KVD824 Phase 2 KOMPLETE trial for HAE prevention on track; data expected mid-2023.
Appointed Patrick A. Treanor (COO of Pathalys Pharma) to Board of Directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.